VIVUS INC
VVUS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VVUS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2020.
Tracking 4 pipeline candidates · 2 clinical trials · 3 FDA decisions for VIVUS INC.
Similar companies
Run VIVUS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available VIVUS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
Profitable (positive operating cash flow)
OCF $114K · Net income -$5M · Debt/OCF 854.6×
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Frequently asked questions
What is VIVUS INC's lead drug candidate?
VIVUS INC's most advanced tracked candidate is pancreaze (Approved) for Exocrine pancreatic insufficiency (EPI).
What therapeutic areas does VIVUS INC focus on?
VIVUS INC develops therapies across Oncology, Cardiovascular, Respiratory, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.